Filana Therapeutics (STU:PX91) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PX91 Filana Therapeutics Inc STU:PX91
37 GF Score
Price €0.78
! 2 Warning Signs
View Full Analysis

What is Filana Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.


STU:PX91 vs BOLD, INKT, XLO: Short Interest Comparison

For the Biotechnology subindustry, Filana Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Filana Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Filana Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Filana Therapeutics's Short Interest falls into.


STU:PX91
37GF Score
Filana Therapeutics Inc STU:PX91
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Filana Therapeutics Business Description

Address 6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
37GF Score

Get the complete analysis for STU:PX91

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.78
Price